SG11201406997WA - Pyrrolotriazinone derivatives - Google Patents

Pyrrolotriazinone derivatives

Info

Publication number
SG11201406997WA
SG11201406997WA SG11201406997WA SG11201406997WA SG11201406997WA SG 11201406997W A SG11201406997W A SG 11201406997WA SG 11201406997W A SG11201406997W A SG 11201406997WA SG 11201406997W A SG11201406997W A SG 11201406997WA SG 11201406997W A SG11201406997W A SG 11201406997WA
Authority
SG
Singapore
Prior art keywords
pyrrolotriazinone derivatives
pyrrolotriazinone
derivatives
Prior art date
Application number
SG11201406997WA
Inventor
Dieter Dorsch
Hans-Peter Buchstaller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201406997WA publication Critical patent/SG11201406997WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
SG11201406997WA 2012-05-04 2013-04-06 Pyrrolotriazinone derivatives SG11201406997WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12003445 2012-05-04
PCT/EP2013/001026 WO2013164061A1 (en) 2012-05-04 2013-04-06 Pyrrolotriazinone derivatives

Publications (1)

Publication Number Publication Date
SG11201406997WA true SG11201406997WA (en) 2014-11-27

Family

ID=48050660

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406997WA SG11201406997WA (en) 2012-05-04 2013-04-06 Pyrrolotriazinone derivatives

Country Status (22)

Country Link
US (1) US9174995B2 (en)
EP (1) EP2844659B1 (en)
JP (1) JP6097820B2 (en)
KR (1) KR20150006873A (en)
CN (1) CN104271580B (en)
AR (1) AR090896A1 (en)
AU (1) AU2013257018B2 (en)
CA (1) CA2872334C (en)
EA (1) EA027628B1 (en)
ES (1) ES2587939T3 (en)
HK (1) HK1205740A1 (en)
HR (1) HRP20161033T1 (en)
HU (1) HUE028325T2 (en)
IL (1) IL235414A (en)
MX (1) MX357502B (en)
PL (1) PL2844659T3 (en)
PT (1) PT2844659T (en)
RS (1) RS55062B1 (en)
SG (1) SG11201406997WA (en)
SI (1) SI2844659T1 (en)
WO (1) WO2013164061A1 (en)
ZA (1) ZA201408876B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2611504T3 (en) 2012-03-07 2017-05-09 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted isoquinolin-1-one compounds and their therapeutic uses
CN105722835B (en) 2013-09-11 2018-07-31 癌症研究协会:皇家癌症医院 3- aryl -5- substitution-isoquinoline-1-ketone compound and their therapy application
PL3087076T3 (en) * 2013-12-23 2018-01-31 Merck Patent Gmbh Imidazopyrazinone derivatives
UY36060A (en) 2014-04-02 2015-10-30 Bayer Pharma AG AZOL COMPOUNDS REPLACED WITH AMIDA
DK3130592T3 (en) 2014-04-10 2019-11-04 Hubei Bio Pharmaceutical Industrial Tech Institute Inc ANALOGS OF 4H-PYRAZOLO [1,5-á] BENZIMIDAZOLE COMPOUNDS AS PARPIN HIBITORS
KR20160007347A (en) 2014-07-11 2016-01-20 에스티팜 주식회사 Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
KR101775356B1 (en) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Method for Determining Susceptibility to Dual Inhibitor against PARP and Tankyrase
DK3356345T3 (en) 2015-09-30 2024-02-12 Max Planck Gesellschaft HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
US10570137B2 (en) * 2015-11-16 2020-02-25 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1 -F] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN109180702B (en) * 2018-10-29 2021-11-30 四川大学 Thienopyrimidone compound and application thereof
CN111961058B (en) * 2020-08-03 2022-12-16 天津全和诚科技有限责任公司 4-amino-pyrrolotriazine derivatives, and preparation method and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
DK0885198T3 (en) 1996-03-05 2002-03-25 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CN1431999A (en) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 Indole derivatives with vascular damagine activity
KR20030014425A (en) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 Colchinol derivatives as vascular damaging agents
AU6623201A (en) 2000-07-07 2002-02-05 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
EP1608631A4 (en) 2003-03-28 2008-08-20 Scios Inc Bi-cyclic pyrimidine inhibitors of tgf beta
CN100594903C (en) 2004-09-30 2010-03-24 泰博特克药品有限公司 HCV inhibiting bi-cyclic pyrimidines
WO2008092861A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
ATE542799T1 (en) 2007-03-08 2012-02-15 Janssen Pharmaceutica Nv QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS
CN101687874B (en) * 2007-04-18 2013-01-30 百时美施贵宝公司 Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
WO2013164061A1 (en) 2013-11-07
IL235414A (en) 2017-11-30
WO2013164061A8 (en) 2014-11-06
CA2872334C (en) 2020-06-30
SI2844659T1 (en) 2016-10-28
CN104271580A (en) 2015-01-07
HRP20161033T1 (en) 2016-10-21
HK1205740A1 (en) 2015-12-24
JP6097820B2 (en) 2017-03-15
US20150133453A1 (en) 2015-05-14
JP2015515961A (en) 2015-06-04
HUE028325T2 (en) 2016-12-28
MX2014013090A (en) 2014-12-08
ES2587939T3 (en) 2016-10-27
AU2013257018A1 (en) 2014-12-18
KR20150006873A (en) 2015-01-19
ZA201408876B (en) 2017-06-28
RS55062B1 (en) 2016-12-30
AR090896A1 (en) 2014-12-17
US9174995B2 (en) 2015-11-03
MX357502B (en) 2018-07-12
EA027628B1 (en) 2017-08-31
EP2844659B1 (en) 2016-05-25
EA201401212A1 (en) 2015-08-31
PT2844659T (en) 2016-08-31
EP2844659A1 (en) 2015-03-11
AU2013257018B2 (en) 2017-02-16
PL2844659T3 (en) 2016-11-30
CA2872334A1 (en) 2013-11-07
CN104271580B (en) 2017-02-22

Similar Documents

Publication Publication Date Title
HUS2200040I1 (en) Benzimidazole-proline derivatives
HK1205740A1 (en) Pyrrolotriazinone derivatives
DK2830816T3 (en) Hidtil ukendt coatingkoncept
HK1207375A1 (en) Piperidinylpyrazolopyridine derivative
HK1205508A1 (en) New bicyclicpyridine derivatives
IL236295A (en) Indanesulfamide derivative
ZA201502175B (en) Oxazolidin-2-one-pyrimidine derivatives
PL2838883T3 (en) New phenyl-tetrahydroisoquinoline derivatives
HK1200824A1 (en) Substituted phenylazole derivative
PT2873660T (en) Indolecarboxamide derivative
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
EP2842958A4 (en) Naphthobisthiadiazole derivative
HK1204621A1 (en) 4-alkanoylamino-3-pyrazolone derivative 4--3-
AU345893S (en) Treehouse